Issue 05 · September 2026

The Big Three Aren’t Just Moving Pills Anymore — They’re Buying the Prescribers

Every pharmaceutical distribution story leads with volume — how many billion doses moved, how thin the margins are on generics. That is the story for the trade press. It is not the story behind the recent wave of dealmaking.

What McKesson, Cencora, and Cardinal Health are actually buying now is not more warehouse throughput. It is the prescriber. Cencora’s push into retina practices and Cardinal’s move into urology and specialty pharmacy networks are bets on owning the point where a prescription gets written, not just the truck that delivers it.

Control the pill, and you’re a vendor. Control the prescriber, and you’re the whole supply chain.

That shift matters because the traditional wholesale business is running out of room. Three companies already handle more than 90 percent of U.S. drug-distribution revenue, and generics margins keep shrinking, so growth increasingly comes from owning specialty pharmacy relationships and the physician groups that drive high-cost drug volume — not from moving more boxes.

For everyone else in the channel, that concentration cuts two ways. Independent pharmacies and regional wholesalers get squeezed on price and access, with less room to negotiate every year. But the specialty practices and physician groups sitting on high-value prescribing volume have suddenly become a scarce, sought-after asset — and most of them have no idea what a group of their size and specialty is actually worth to a buyer racing to lock down the prescriber before a competitor does.

The overlooked opportunity is on that side of the table: the practice owner who would rather understand their options and choose the right partner than field a single unsolicited offer and assume it’s the market price.

— Autotrend Partners connects independent pharmacies, specialty practices, and physician groups with the capital and distribution partners courting them, across pharmaceutical wholesale consolidation.